Read more
5:32 PM · 21 February 2023

Vir Biotechnology surges after Goldman upgrade

-
-
Open account Download free app

Vir Biotechnology (VIR.US) shares rose over 8.0% on Tuesday after  Goldman Sachs  upgraded the immunology company to buy from neutral and lifted its price target to $53 from $41. Bank believes the stock could double, citing Vir’s release of flu vaccine data in the year ahead.

"And though the flu market expanded significantly during the COVID pandemic to $8bn with 1bn doses delivered in 2021 (+29% vs. 2019), our conservative assumptions nevertheless support 2030 risk-adjusted (60% PoS) sales of $2.3bn (vs. just $700mn for consensus)" analysts wrote.

Analysts also pointed to "compelling risk/reward for an underappreciated catalyst with the potential to drive a major new leg of growth."

Vir Biotechnology (VIR.US) launched today's session with nearly 14.0% bullish price gap, however buyers gave back some gains later in the session as overall sentiment deteriorated further. Currently price is approaching local support at $27.00, which coincides with 23.6% Fibonacci retracement of the downward wave started in December 2021. Should break lower occur, price may move towards recent lows at $24.65 and 200 SMA (red line). Nevertheless as long as price sits above $27.00 handle, upward move have a chance to resume. Nearest resistance to watch lies at $31.60, marked by previous price reactions and lower limit of the 1:1 structure. Source: xStation5

9 March 2026, 5:40 PM

Live Nation climbs on antitrust deal

9 March 2026, 4:30 PM

Is the FDA sabotaging medical companies? UniQure’s valuation rollercoaster

9 March 2026, 1:53 PM

US Open: Oil too expensive for Wall Street!

9 March 2026, 1:02 PM

Further cracks in the private credit market: BlackRock limits withdrawals

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits